Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

pharmacological treatment by Opioids

PreclinicalSmall molecule

UUniversidad Europea de Canarias

pharmacological treatment by Opioids is one of 2 small molecule programs targeting Neuromodulation. It is currently in Preclinical.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeuromodulationWithdrawn

NeuromodulationPreclinical

Withdrawn

Competition

Competitive Landscape

1 competitor in Neuromodulation

#DrugCompanyPhaseTrials

Drug Therapy

MMassachusetts General Hospital

pharmacological treatment by Opioids

UUniversidad Europea de Canarias

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neuromodulation1 trial

Effectiveness of Percutaneous Neuromodulation vs Pharmacological Treatment in Cancer Patients With Anterior Knee Pain

Withdrawn·UUniversidad Europea de Canarias·N/A·NCT06240390

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for pharmacological treatment by Opioids. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — pharmacological treatment by Opioids compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for pharmacological treatment by Opioids. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Universidad Europea de Canarias company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversidad Europea de Canarias

Related News